A Phase 2 interventional study of 18F-MK6240 injection in Diabetes Mellitus, Type 2 and Pre-diabetes, sponsored by Columbia University. Enrolling by invitation at 1 site in United States. Open to participants aged 55 Years to 69 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-05-06.
Sponsored by Columbia University · Phase 2, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies in Diabetes Mellitus, Type 2 by Columbia University — 3 open to participants now, 3 under way, none of them phase 3. Diabetes Mellitus, Type 2 · Columbia University.
Among the 13 studies in Diabetes Mellitus, Type 2 by Columbia University, this one is the 2nd largest by planned enrollment of the 11 interventional ones that give a count, is one of 3 that started in 2018, is the only one in phase 2, and was the 4th registered.
10,396 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →3 of the 13 studies in Diabetes Mellitus, Type 2 by Columbia University are open now, in 1 country. Recruiting first, the newest first:
Columbia University · Sites in United States
Ages 18–70 · Healthy volunteers
Columbia University · Sites in United States
Ages 20+
By country, each count listing its studies:
Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 381 (43%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.
This study: 55 Years to 69 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
First in 1996; this study’s year is marked. 3 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 600 is above the median of 80 across 8,367 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 55 across the 11 interventional studies, 142 across the 2 observational. Of the 10 that completed or were terminated, 2 (20%) have results posted.
This tab as a report to print or save as PDF → With an account.
Columbia University is the lead sponsor of 1,136 studies on the registry; 195 are open to participants now.
Of its 182 completed or terminated interventional studies of FDA-regulated products, 150 (82%) have results posted.
1 of the studies in Diabetes Mellitus, Type 2 by Columbia University that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07620808Columbia UniversityMTM2MTG Pilot Ancillary Study | 2027-06 |
Add it to your calendar (.ics) → With an account.
Among the 13 studies in Diabetes Mellitus, Type 2 by Columbia University, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a single center brain Positron Emission Tomography (PET) study of 18F-MK-6240. Eligible participants are persons from Northern Manhattan who self-identify as Hispanic, non-Hispanic Black, or Non-Hispanic White, who are 55 to 69 years of age, of both sexes, without dementia, who have already agreed to undergo, of have undergone, brain amyloid PET and magnetic resonance imaging (MRI). Those eligible will have one brain PET scan with 18F-MK-6240, repeated after 18 months to 30 months. Vital signs will be checked prior to injection of 18F-MK-6240 and again at the completion of the PET scan. The primary objective is to relate diabetes status and glycemia to in-vivo brain tau accumulation, across and within ethnic and racial groups.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Breastfeeding women will be excluded, although we expect this situation to be rare
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
intravenous injection of 18F-MK-6240, up to 5 mCi (185 MBq), IV, total of one injection per PET scan (2 injections in total with an interval of 18 to 30 months)
Drug: 18F-MK6240 injection
Intravenous injection of 18F-MK-6240, up to 5 mCi (185 MBq), total of one injection per PET scan (2 injections in total with an interval of 18 to 30 months)
Also known as: MK6240
18F-MK6240 standardized update value ratio (SUVR)
The primary outcome measure will be regional standardized uptake value ratio (SUVR) values for 18F-MK-6240 using cerebellum as reference region. Kinetic modeling using Logan DVR method may also be employed. Multiple brain regions will be measured, with particular attention to medial temporal cortex structures such as hippocampus and entorhinal cortex
Time frame: 18 to 30 months
Plan to share: Yes — We plan to share data with the data sharing platform of the NIA consortium named "Molecular Mechanisms of the Vascular Etiology of Alzheimer's disease (M2OVE-AD)" for data collection supported by grant RF1AG051556. This data sharing platform is called Synapse, and is managed by SAGE bionetworks. The main data from this protocol to be shared are summary values of brain Tau SUVR, demographics, and clinical variables such as diabetes status.
Supporting information: Study protocol
Time frame: Data will be released twice a year to SAGE bionetworks for sharing.
Access criteria: Synapse operates under comprehensive governance policies. These policies delineate Synapse users' rights and responsibilities. They also specify the rights and responsibilities of Sage Bionetworks and of the Synapse Access and Compliance Team (ACT).
Data sharing details ↗ · help.synapse.org
Started Jul 2018 (actual). Primary completion is estimated for Jun 2026, 95 months after the start.
Of 99 non-industry phase 2 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 50. This study's planned 95 months is above that.
Counting every sponsor, half of 293 studies reached it within 15 months; a quarter within 11 and three quarters within 27.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.